# Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

> **NCT00103376** · PHASE2 · TERMINATED · sponsor: **Medical University of South Carolina** · enrollment: 23 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Velcade
- **DRUG:** LH-RH Agonist
- **DRUG:** Androgen Receptor Antagonists

## Key facts

- **NCT ID:** NCT00103376
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10
- **Primary completion:** 2009-10
- **Final completion:** 2011-06
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Low Accrual
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103376, "Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00103376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*